H.C. Wainwright Reiterates Genocea Biosciences (GNCA) at Buy with $9 Price Target, Remains Optimistic of GEN-011 Antitumor Efficacy and Durability, Sees Significant "Value-generating Potential"
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $9.00 price target on Genocea Biosciences (NASDAQ: GNCA), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
